Evidence map›Paper›PMID 41869808›Full record

ArticleMicrobiology spectrum2026

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales.

Sean R Van Helden, Ashlan J Kunz Coyne, Sara Alosaimy, Abdalhamid M Lagnf, Kyle C Molina, S Lena Kang-Birken, Kimberly C Claeys, Mark Biagi, Justin Andrade, Alaina DeKerlegand and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sean R Van HeldenDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0009-0000-2277-7089
Ashlan J Kunz CoyneDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0000-0002-4891-8625
Sara AlosaimyDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Abdalhamid M LagnfDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Kyle C MolinaUniversity of Colorado Anschutz School of Medicine, Aurora, Colorado, USA.
S Lena Kang-BirkenSanta Barbara Cottage Hospital, Santa Barbara, California, USA.
Kimberly C ClaeysUniversity of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0001-6895-604X
Mark BiagiUW Health SwedishAmerican Hospital, Rockford, Illinois, USA.
Justin AndradeTouro College of Pharmacy, The Brooklyn Hospital Center, New York, New York, USA.
Alaina DeKerlegandOur Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, USA.
Melanie Rae SchrackOur Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, USA.
Tristan GoreCollege of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Madeline A KingPhiladelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, USA.
Benjamin M PullingerPhiladelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, USA.
Serina TartCape Fear Valley Health, Fayetteville, North Carolina, USA.
Athena L V HobbsMethodist University Hospital, Memphis, Tennessee, USA.
Jazmin AgeeMethodist University Hospital, Memphis, Tennessee, USA.
Nicholson B PerkinsMethodist University Hospital, Memphis, Tennessee, USA.
Michael P VeveDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Reese CosimiAscension St. Vincent Hospital, Indianapolis, Indiana, USA.
Shelbye R HerbinDepartment of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA.
Bruce M JonesSt. Joseph's/Candler Health System, Savannah, Georgia, USA.
Amy K Feehan CurleyOchsner Clinic Foundation, New Orleans, Louisiana, USA.
Chloe JuddDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Mohammed Al MusawaDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Michael J RybakDepartment of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0000-0003-2220-0081

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial species in the Enterobacterales order are commonly encountered causative organisms in hospital-acquired infections. Furthermore, the incidence of carbapenem-resistant Enterobacterales (CRE) is a growing threat worldwide. Eravacycline (ERV) is a broad-spectrum fluorocycline antibiotic with activity against Enterobacterales, including CRE, and is approved for the treatment of complicated intra-abdominal infections (cIAI) in the United States and Europe. We conducted a subpopulation analysis of a previously published real-world study evaluating the efficacy of eravacycline for the treatment of infections involving Enterobacterales. Adult patients who received eravacycline for ≥72 h for any infection type involving an Enterobacterales organism were included. The primary outcome was clinical success, and secondary outcomes comprised 30-day all-cause and in-hospital mortality, 30-day microbiological and symptomatic recurrence, and 30- and 60-day hospital readmission. A total of 155 patients were eligible for inclusion. The primary causative organisms were

Indexed as

antibiotic resistancebeta-lactamasescarbapenem-resistant EnterobacteralesCREEnterobacteraleseravacyclineERVEscherichia coliKlebsiellametallo-beta-lactamasemultidrug resistancetetracycline

Identifiers

PMID41869808
PMCPMC13141925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.